The closing price of TRACON Pharmaceuticals Inc (NASDAQ: TCON) was $0.19 for the day, up 0.27% from the previous closing price of $0.19. In other words, the price has increased by $+0.0005 from its previous closing price. On the day, 869144 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of TCON’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.71 and its Current Ratio is at 0.71.
On February 10, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $24.
H.C. Wainwright reiterated its Buy rating for the stock on December 23, 2019, while the target price for the stock was revised from $15 to $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 27 when THEUER CHARLES bought 47,000 shares for $0.75 per share. The transaction valued at 35,250 led to the insider holds 399,417 shares of the business.
THEUER CHARLES bought 3,999 shares of TCON for $2,639 on Apr 26. The President and CEO now owns 352,417 shares after completing the transaction at $0.66 per share. On Mar 09, another insider, Opaleye Management Inc., who serves as the 10% Owner of the company, bought 174,508 shares for $1.38 each. As a result, the insider paid 240,821 and bolstered with 4,324,508 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCON now has a Market Capitalization of 5.86M and an Enterprise Value of -1.57M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.65. Its current Enterprise Value per Revenue stands at -0.17 whereas that against EBITDA is 0.58.
Stock Price History:
Over the past 52 weeks, TCON has reached a high of $2.19, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.1820, while the 200-Day Moving Average is calculated to be 0.2627.
Shares Statistics:
TCON traded an average of 1.67M shares per day over the past three months and 709.15k shares per day over the past ten days. A total of 31.14M shares are outstanding, with a floating share count of 26.47M. Insiders hold about 14.99% of the company’s shares, while institutions hold 16.41% stake in the company. Shares short for TCON as of Feb 15, 2024 were 856.28k with a Short Ratio of 0.51, compared to 853.05k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.75% and a Short% of Float of 3.67%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.11, while EPS last year was -$0.31. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.16 and -$0.25 for the fiscal current year, implying an average EPS of -$0.2. EPS for the following year is -$0.4, with 3 analysts recommending between -$0.28 and -$0.59.
